STOCK TITAN
  1. Home
  2. Financials
  3. BFNH

Bioforce Nanosciences Hldgs In Financials

BFNH
Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Bioforce Nanosciences Hldgs In (BFNH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BFNH FY2025

Balance-sheet repair came from liabilities shrinking, while the company still operated with an almost nonexistent asset base.

Between FY2024 and FY2025, liabilities fell from $2.3M to $619K, which is the main reason the balance sheet looks less strained. Assets did not recover with it: year-end assets were only $786 and the current ratio was 0.0013x, so the improvement reflects smaller claims, not a rebuilt operating base.

Shares outstanding rose to 33.5M from 29.3M across the last year shown. Yet cash and total assets were still under $1K at year-end, a sign of dilution without replenishment rather than a meaningful restoration of financial resources.

Some figures from recent filings were inconsistent and were omitted from this summary.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 16 / 100
Financial Profile 16/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Bioforce Nanosciences Hldgs In's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage
97

Bioforce Nanosciences Hldgs In carries a low D/E ratio of -1.00, meaning only $-1.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity
0

Bioforce Nanosciences Hldgs In's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
N/A
EPS (Diluted)
$-0.04
YoY-100.0%

Bioforce Nanosciences Hldgs In earned $-0.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$786
YoY-8.8%
5Y CAGR-54.4%

Bioforce Nanosciences Hldgs In held $786 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
34M
YoY+14.5%
5Y CAGR+2.7%

Bioforce Nanosciences Hldgs In had 34M shares outstanding in fiscal year 2025. This represents an increase of 14.5% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
N/A

BFNH Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses $12K N/A N/A N/A $28K N/A N/A N/A
Operating Income N/A N/A N/A N/A N/A N/A N/A N/A
Interest Expense N/A N/A N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income N/A N/A N/A N/A N/A N/A N/A N/A
EPS (Diluted) $0.00 N/A $0.00 $0.00+100.0% $-0.03 N/A $0.00 $0.00

BFNH Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $6K+707.5% $786+0.3% $784-13.4% $905-93.4% $14K+1500.8% $862-47.3% $2K+145.1% $667
Current Assets $6K+707.5% $786+0.3% $784-13.4% $905-93.4% $14K+1500.8% $862-47.3% $2K+145.1% $667
Cash & Equivalents $6K+707.5% $786+0.3% $784-13.4% $905-93.4% $14K+1500.8% $862-47.3% $2K+145.1% $667
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $727K+17.4% $619K+23.7% $501K+30.1% $385K+40.0% $275K-88.1% $2.3M+5.6% $2.2M+5.6% $2.1M
Current Liabilities $727K+17.4% $619K+23.7% $501K+30.1% $385K+40.0% $275K-88.1% $2.3M+5.6% $2.2M+5.6% $2.1M
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity -$721K-16.6% -$619K-23.7% -$500K-30.2% -$384K-46.5% -$262K+88.6% -$2.3M-5.7% -$2.2M-5.5% -$2.1M
Retained Earnings -$162.5M-0.1% -$162.4M-0.1% -$162.3M-0.1% -$162.2M-0.1% -$162.1M-0.6% -$161.1M-0.1% -$161.0M-0.1% -$160.9M

BFNH Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow $7K N/A N/A N/A -$15K N/A N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow -$2K N/A N/A N/A $28K N/A N/A N/A
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

BFNH Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A N/A N/A N/A
Current Ratio 0.010.0 0.000.0 0.000.0 0.00-0.0 0.05+0.0 0.000.0 0.000.0 0.00
Debt-to-Equity -1.010.0 -1.000.0 -1.000.0 -1.00+0.0 -1.05-0.0 -1.000.0 -1.000.0 -1.00
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$619K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

Bioforce Nanosciences Hldgs In (BFNH) reported diluted earnings per share of $-0.04 for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bioforce Nanosciences Hldgs In (BFNH) had $786 in total assets as of fiscal year 2025, including both current and long-term assets.

Bioforce Nanosciences Hldgs In (BFNH) had 34M shares outstanding as of fiscal year 2025.

Bioforce Nanosciences Hldgs In (BFNH) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Bioforce Nanosciences Hldgs In (BFNH) had a debt-to-equity ratio of -1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Bioforce Nanosciences Hldgs In (BFNH) has negative shareholder equity of -$619K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Bioforce Nanosciences Hldgs In (BFNH) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top